Risk of post-thrombotic syndrome following direct oral anticoagulant intake: a systematic review and meta-analysis

Lobastov K.V.; Schastlivtsev I.V.; Bargandzhiya A.B.

doi:https://doi.org/10.17116/hirurgia202202189

Close metadata

OBJECTIVE

To perform a systematic review and meta-analysis of data devoted to the risk of post-thrombotic syndrome (PTS) following direct oral anticoagulant (DOAC) intake.

MATERIAL AND METHODS

A systematic review and meta-analysis of trials available in the PubMed database were performed in March 2021. Analysis included the reports with known Villalta score for PTS in patients receiving DOACs or alternative anticoagulation. We analyzed the incidence and risk of any form of PTS.

RESULTS

We found 10 comparative studies comprising 3161 patients. Incidence of PTS under DOAC therapy was 30.8% (95% confidence interval (CI) 22.2—39.3%), severe PTS — 2.2% (95% CI 1.0—3.4%). DOACs were associated with significantly less risk of any form of PTS (odds ratio (OR) 0.57; 95% CI 0.48—0.68; p<0.001) and severe PTS (OR 0.56; 95% CI 0.36—0.87; p=0.010) compared to vitamin K antagonists. Among various DOACs, specified data were available only for rivaroxaban (OR 0.54, 95% CI 0.42—0.71, p<0.001 for any PTS; OR 0.49, 95% CI 0.27—0.89, p=0.019 for severe PTS). The use of flavonoids in adjunction to rivaroxaban was associated with additional risk reduction for PTS (OR 0.14; 95% CI 0.06—0.31; p<0.001).

CONCLUSION

Moderate quality evidence suggests that DOACs are associated with significant less risk of any PTS and severe PTS compared to VKA in patients with deep vein thrombosis. Among all DOACs, only rivaroxaban has clear data confirming PTS risk reduction. The use of flavonoids in adjunction to rivaroxaban can further improve treatment outcomes.

Keywords:

direct oral anticoagulants

rivaroxaban

post-thrombotic disease

treatment

prevention

Authors:

Lobastov K.V.

Pirogov’s Russian National Research Medical University

ORCID: 0000-0002-5358-7218

Schastlivtsev I.V.

Pirogov’s Russian National Research Medical University

ORCID: 0000-0002-1306-1502

Bargandzhiya A.B.

Pirogov Russian National Research Medical University

ORCID: 0000-0003-3757-8861

Received:

12.04.2021

Accepted:

21.05.2021

Close metadata

References:

Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Ginsberg JS. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost. 2008;6(7):1105-1112. https://doi.org/10.1111/j.1538-7836.2008.03002.x
Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82(4):423-428.
Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7. https://doi.org/10.7326/0003-4819-125-1-199607010-00001
Zolotukhin IA, Seliverstov EI, Shevtsov YuN, Avakiants IP, Nikishkov AI, Tatarintsev AM, Kirienko AI. Prevalence of Chronic Venous Disease: Results of Population Based Epidemiological Study. Flebologiya. 2016;10(3):119-125. (In Russ.). https://doi.org/10.17116/flebo2016103119-125
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14. https://doi.org/10.1007/s11239-015-1311-6
The incidence of the entire population of Russia in 2016. Statistical materials Part II. 2017. (In Russ.). https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2016-god
Ryzhkin VV, Lobastov KV, Laberko LA, Rodoman GV. Following from deep vein thrombosis to post-thrombotic syndrome: mechanisms of formation and risk factors. Hirurg. 2017;8:31-45. (In. Russ.).
Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, Weitz JI. American Heart Association Council on Peripheral Vascular Disease, C.o.C.C., Council on, C., Stroke, N., The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636-1661. https://doi.org/10.1161/CIR.0000000000000130
Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med. 2011;124(8):756-765. https://doi.org/10.1016/j.amjmed.2011.02.033
Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Journal of Thrombosis and Haemostasis. 2009;102(2):258-267. https://doi.org/10.1160/TH08-12-0832
van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968-1975. https://doi.org/10.1182/blood-2014-04-571232
Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor’s Choice — A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. Eur J Vasc Endovasc Surg. 2019;57(5):685-701. https://10.1016/j.ejvs.2018.11.004
Desai R, Koipallil GK, Thomas N, Mhaskar R, Visweshwar N, Laber D, Patel A, Jaglal M. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Sci Rep. 2020;10(1):18945. https://doi.org/10.1038/s41598-020-75863-3
Ramacciotti E, Volpiani GG, Davila R, Resende VA, Silveira FM, Fareed J, Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again? International angiology: a journal of the International Union of Angiology. 2018;37(1):1-3.
Papadaki S, Tselepis AD. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants? Angiology. 2019;70(10):896-907. https://doi.org/10.1177/0003319719840861
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
Study Quality Assessment Tools. [cited 2021 29.03]. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898
Current version of RoB 2. 2019 [cited 2021 29.03]. https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2
Cheung YW, Middeldorp S, Prins MH, Pap AF, Lensing AW, Ten Cate-Hoek AJ, Villalta S, Milan M, Beyer-Westendorf J, Verhamme P, Bauersachs RM, Prandoni P. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost. 2016;116(4):733-738. https://doi.org/10.1160/th16-01-0041
Schastlivtsev I, Lobastov K, Barinov V, Kanzafarova I. Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study. Int Angiol. 2020;39(5):361-371. https://doi.org/10.23736/S0392-9590.20.04356-4
Lobastov K, Schastlivtsev I, Barinov V. Use of Micronized Purified Flavonoid Fraction Together with Rivaroxaban Improves Clinical and Ultrasound Outcomes in Femoropopliteal Venous Thrombosis: Results of a Pilot Clinical Trial. Adv Ther. 2019;36(1):72-85. https://doi.org/10.1007/s12325-018-0849-z
de Athayde Soares R, Matielo MF, Brochado Neto FC, Nogueira MP, Almeida RD, Sacilotto R. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery. 2019;166(6):1076-1083. https://doi.org/10.1016/j.surg.2019.05.030
Campello E, Spiezia L, Simion C, Tormene D, Camporese G, Dalla Valle F, Poretto A, Bulato C, Gavasso S, Radu Claudia M, Simioni P. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. Journal of the American Heart Association. 2020;9(23):e018917. https://doi.org/10.1161/JAHA.120.018917
Prandoni P, Ageno W, Ciammaichella M, Mumoli N, Zanatta N, Imberti D, Visonà A, Bucherini E, Di Nisio M, Noventa F. The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. Intern Emerg Med. 2020;15(3):447-452. https://doi.org/10.1007/s11739-019-02215-z
Sebastian T, Hakki LO, Spirk D, Baumann FA, Periard D, Banyai M, Spescha RS, Kucher N, Engelberger RP. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. Thromb Res. 2018;172:86-93. https://doi.org/10.1016/j.thromres.2018.10.027
Ferreira T, Huber SC, de Moraes Martinelli B, Junior AL, Menezes FH, Orsi FA, Bittar LF, de Oliveira LFG, Sodre LR, Mello TT, Rielli G, Colella MP, de Paula EV, Yamaguti-Hayakawa GG, Montalvão S, Annichino-Bizzacchi JM. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban. Vascul Pharmacol. 2020;124:106608. https://doi.org/10.1016/j.vph.2019.106608
Utne KK, Dahm A, Wik HS, Jelsness-Jørgensen LP, Sandset PM., Ghanima W. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res. 2018;163:6-11. https://doi.org/10.1016/j.thromres.2018.01.013
Jeraj L, Jezovnik MK, Poredos P. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thromb Res. 2017;157:46-48. https://doi.org/10.1016/j.thromres.2017.05.029
Utne KK, Ghanima W, Foyn S, Kahn S, Sandset PM, Wik HS. Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome. Thromb Haemost. 2016;115(2):361-367. https://doi.org/10.1160/th15-04-0318
Li R, Yuan M, Cheng J, Yu S, Wei W, Fu W, Prandoni P, Chen Y. Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis. Thromb Res. 2020;196:340-348. https://doi.org/10.1016/j.thromres.2020.09.014
Kyrle PA. How I treat recurrent deep-vein thrombosis. Blood. 2016;127(6):696-702. https://doi.org/10.1182/blood-2015-09-671297
Lobastov K, Ryzhkin V, Vorontsova A, Schastlivtsev I, Barinov V, Laberko L, Rodoman G. Electrical calf muscle stimulation in patients with post-thrombotic syndrome and residual venous obstruction after anticoagulation therapy. Int Angiol. 2018;37(5):400-410. https://10.23736/S0392-9590.18.03997-4
Mearns ES, Kohn CG, Song JS, Hawthorne J, Meng J, White CM, Raut MK, Schein JR, Coleman CI. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res. 2014;134(2):310-319. https://doi.org/10.1016/j.thromres.2014.05.035
Nicklas JM, Gordon AE, Henke PK. Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms. Int J Mol Sci. 2020;21(6). https://doi.org/10.3390/ijms21062080
Budnik I, Brill A. Immune Factors in Deep Vein Thrombosis Initiation. Trends Immunol. 2018;39(8):610-623. https://doi.org/10.1016/j.it.2018.04.010
Deroo S, Deatrick KB, Henke PK. The vessel wall: A forgotten player in post thrombotic syndrome. Thromb Haemost. 2010;104(4):681-692. https://doi.org/10.1160/th10-03-0183
Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness DE, Jr. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg. 1993;18(4):596-605; discussion 606-608.
Chandrashekar A, Garry J, Gasparis A, Labropoulos N. Vein wall remodeling in patients with acute deep vein thrombosis and chronic postthrombotic changes. J Thromb Haemost. 2017;15(10):1989-1993. https://doi.org/10.1111/jth.13793
Candido S, Lumera G, Barcellona G, Vetri D, Tumino E, Platania I, Frazzetto E, Privitera G, Incognito C, Gaudio A, Signorelli SS. Direct oral anticoagulant treatment of deep vein thrombosis reduces IL-6 expression in peripheral mono-nuclear blood cells. Exp Ther Med. 2020;20(6):237. https://doi.org/10.3892/etm.2020.9367
Piati PK, Peres AK, de Andrade DO, Jorge MA, Toregeani JF. Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban. J Vasc Bras. 2019;18:e20180111. https://doi.org/10.1590/1677-5449.180111
Prandoni P, Ageno W, Mumoli N, Zanatta N, Imberti D, Visonà A, Ciammaichella M, Simioni L, Cappelli R, Bucherini E, Di Nisio M, Avruscio G, Camporese G, Parisi R, Cuppini S, Turatti G, Noventa F, Sarolo L. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res. 2017;153:97-100. https://doi.org/10.1016/j.thromres.2017.03.022
Ning J, Ma W, Fish J, Trihn F, Lurie F. Biases of Villalta scale in classifying post-thrombotic syndrome in patients with pre-existing chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2020;8(6):1025-1030. https://doi.org/10.1016/j.jvsv.2020.01.018
Franzeck UK, Schalch I, Jager KA, Schneider E, Grimm J, Bollinge A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation. 1996;93(1):74-79. https://doi.org/10.1161/01.cir.93.1.74